



МлагОнколог

Challenges & Controversies in Medical Oncology

Sunny beach, May 17-20, 2018

Programme

May 17, Thursday

14.00 – 19.00 Accommodation and Registration
19.00 – 22.00 Dinner

May 18, Friday

09.50 – 09.40 Opening Ceremony – R. Krasteva

FIRST PLENARY SESSION – LUNG CANCER Moderators: N.Chilingirova & R. Djupanova

09.40 – 10.00 EGFR tyrosine kinase inhibitors in the adjuvant therapy of completely resected NSCLC – R. Pirker
10.00 – 10.20 Advanced NSCLC: medical management from unselected flooding to precision therapy – Chr. Manegold
10.20 – 10.40 Management of SCLC – K. Botsolis
10.40 – 11.00 Immunotherapy in Lung Cancer – S. Baka
11.00 – 11.20 Lung Cancer Screening - Challenges and Unsolved Issues – W. Voigt
11.20 – 11.40 Coffee Break
11.40 – 12.00 How to stay motivated and calm in stressful situations at work – A. Juškevičienė
12.00 – 12.20 Anti-PDL1 immunotherapy with atezolizumab in NSCLC – “all comers” – A. Konsoulova
12.20 – 12.40 Osimertinib – clinical trials results in patients with T790M mutated NSCLC and the effect on brain metastasis – N. Tsonev
12.40 – 13.40 Lunch

SECOND PLENARY SESSION – COLON CANCER Moderators: Iv. Stoyanova & L.Vasilev

13.40 – 14.00 Diagnostics Biomarkers in Colon Cancer – D. Dimitrov
14.00 – 14.20 Continuum of care for Wild Type RAS Metastatic Colorectal Cancer patients – L. Simeonova
14.20 – 14.40 Role of Stereotactic Body Radiation Therapy (SBRT) in oligometastatic colorectal cancer: An opportunity for cure? – N. Velikova
14.40 – 15.00 Metastatic colon cancer – chemotherapy or immunotherapy – challenges and controversies – T. Zlatanova
15.00 – 15.20 Percutaneous Ablation of Colon Cancer Liver Metastases – J. Genov, R. Mitova
15.20 – 15.40 PET - CT Diagnostics in Colon Cancer: Challenges and Current Issues – J. Mihailovic
15.40 – 16.00 Coffee Break
16.00 – 16.40 Sanofi Genzyme Symposium - Biomarker data utility in tailoring treatment decisions in mCRC Plasma and tissue biomarkers in mCRC: retrospective analyses of the VELOUR trial – I. Tonev mCRC Clinical case 1 – M. Kyoseva; mCRC Clinical case 2 – E. Tazimova

THIRD PLENARY SESSION – PROSTATE CANCER Moderator: S. Nedeva

16.40 – 17.20 Astellas Symposium - Changing our approach towards mCRPC and the challenges of the day – R. Krasteva, K. Ivanov
17.20 – 17.40 Imaging Tests and Staging of Prostate Cancer – P. Getsov; Repositioning current therapeutic options for advanced prostate cancer. Abiraterone acetate (Zytiga®): vision to 2018 – J. Assa
17.40 – 18.00 New treatment option for patients with Metastatic Urothelial Carcinoma - Atezolizumab, the anti-PDL1 Immunotherapy – K. Kalacheva
18.00 – 18.20 Nuclear Medicine Approaches in Prostate Cancer – Challenges and Controversies – S. Sergieva
18.20 – 19.20 POSTER SESSION
20.00 – 22.00 Dinner

May 19, Saturday

FOURTH PLENARY SESSION – KEYNOTE LECTURES Moderators: S. Katev & Hr. Spassov

09.50 – 10.00 Personalized Therapy: How to Test Cost-Effectively and Evidence-Based for Predictive Markers – M. Papotti
10.00 – 10.50 Basics in Clinical Statistics – L. Pilz
10.50 – 11.00 Challenges and controversies in breast conserving surgery – G. Zografos
11.00 – 11.20 Supermicrosurgery for Treatment of Postoperative Lymphoedema: What We Know and What We Don't? – Y. Yordanov
11.20 – 11.40 Issues with Anticancer Drug Availability and Access – A. Konsoulova
11.40 – 12.00 Personalized Medicine – What is the Situation in Bulgaria – Y. Drenski
12.00 – 12.15 Coffee Break
12.15 – 13.00 Symposium Eli Lilly - Real experience with Cyramza – R. Krasteva, K. Genova
13.00 – 14.00 Lunch

FIFTH PLENARY SESSION BREAST CANCER Moderators: M. Koleva & A. Konsoulova

14.00 – 14.20 PET-CT in Breast Cancer - Challenges and Unsolved Issues – Q. Siraj
14.20 – 14.40 Sentinel Lymph Node Dissection - Challenges and Controversies – D. Pinto
14.40 – 15.00 Screen Detected Cancer - Micro Tumors with Macro Approach. Are we acting or we are hiding? – V. Ivanov
15.00 – 15.20 Management of Pregnant Patients with Breast Cancer: Gynecology Aspects – V. Stoykova
15.20 – 15.40 Breast Cancer during Pregnancy – A. Konsoulova
15.40 – 16.00 Male Breast Cancer – R. Krasteva
16.00 – 16.10 Coffee Break
16.10 – 16.50 Target Therapy of HER 2 Positive Metastatic Breast Cancer – M. Koleva
16.50 – 16.50 Management of Triple Negative Breast Cancer - F. Zagouri
16.50 – 17.50 Boehringer Ingelheim Symposium - The Modern Approach to the Diagnosis and Treatment of NSCLC – M. Gottfried
17.50 – 18.10 Changing the treatment paradigm in HR+/HER2- mBC: The impact of Ibrance (Palbociclib) and the new CDK 4/6 generation – A. Konsoulova
18.10 – 18.50 MSD Symposium - Pembrolizumab - A New Paradigm in Cancer Treatment The New Standard in the Treatment of Advanced NSCLC – N. Chilingirova Metastatic Urothelial Cancer - the Role of PD-1 Inhibitors in the Treatment – A. Konsoulova
20.00 – 25.00 Dinner